{"id":51928,"date":"2022-12-13T17:02:19","date_gmt":"2022-12-13T16:02:19","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/pharmajet-partner-immunomic-therapeutics-receives-fda-fast-track-designation-for-pdna-vaccine-for-skin-cancer\/"},"modified":"2022-12-13T17:02:19","modified_gmt":"2022-12-13T16:02:19","slug":"pharmajet-partner-immunomic-therapeutics-receives-fda-fast-track-designation-for-pdna-vaccine-for-skin-cancer","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/pharmajet-partner-immunomic-therapeutics-receives-fda-fast-track-designation-for-pdna-vaccine-for-skin-cancer\/","title":{"rendered":"PharmaJet Partner Immunomic Therapeutics Receives FDA Fast Track Designation for pDNA Vaccine for Skin Cancer"},"content":{"rendered":"
\n

\nVaccine exclusively delivered with the PharmaJet Stratis\u00ae<\/sup> Needle-free Injection System<\/i>\n<\/p>\n

GOLDEN, Colo.–(BUSINESS WIRE)–PharmaJet<\/a>\u00ae<\/sup>, a company that engineers precision delivery systems that overcome the challenges of vaccine and pharmaceutical companies, today announced that their partner Immunomic Therapeutics<\/a> received FDA fast track designation (FTD) for the clinical study of their plasmid DNA vaccine ITI-3000 in patients with Merkel cell carcinoma (MCC), a rare but aggressive form of skin cancer. Enrollment is in progress for the phase 1 study that exclusively uses the PharmaJet Stratis Needle-free Injection System (NFIS).\n<\/p>\n

<\/a><\/p>\n

\n\u201cThe FDA\u2019s decision to grant FTD underscores the potential for the ITI-3000 program to address a serious unmet need and serve as a meaningful therapeutic option for patients with Merkel cell carcinoma,\u201d stated Dr. William Hearl, Chief Executive Officer of ITI. \u201cWe are committed to unlocking the full potential of ITI-3000 in patients with this aggressive form of skin cancer. We expect to report top-line data from our ongoing phase 1 trial of ITI-3000 in MCC patients next year and look forward to working closely with the FDA on a potential next phase clinical study design, while simultaneously continuing dialogue with possible partners.\u201d The PharmaJet Stratis\u00ae<\/sup> NFIS was chosen due to its ability to precisely deliver the vaccine to the intramuscular tissue layer.\n<\/p>\n

\n\u201cWe are pleased that our partner Immunomic Therapeutics has received fast track designation for this important DNA therapeutic for aggressive skin cancer,\u201d said Chris Cappello, President and CEO, PharmaJet. \u201cThe PharmaJet NFIS have been used successfully in administration of therapeutics for the prevention or treatment of lymphoma, advanced solid tumors, HPV and other oncology applications.\u201d\n<\/p>\n

\nFor more information about PharmaJet visit https:\/\/pharmajet.com<\/a>.\n<\/p>\n

\nRefer to Instructions for Use to ensure safe injections and to review <\/i>risks.<\/i>\n<\/p>\n

\nAbout PharmaJet<\/b>\n<\/p>\n

\nPharmaJet\u2019s vision is to enable greater access to life-saving vaccines and pharmaceuticals globally. We are committed to helping our partners realize their research and commercialization goals while making an impact on public health. PharmaJet Needle-free Systems provide increased vaccine effectiveness, a preferred patient and caregiver experience, and a proven path to commercialization. They are also safe, fast, and easy-to-use. The Stratis\u00ae <\/sup>System has U.S. FDA 510(k) marketing clearance, CE Mark, and WHO PQS certification to deliver medications and vaccines either intramuscularly or subcutaneously. The Tropis\u00ae<\/sup> System has CE Mark and WHO PQS certification for intradermal injections. For more information visit https:\/\/pharmajet.com<\/a>. Follow us on LinkedIn<\/a>.\n<\/p>\n

\nAbout Immunomic Therapeutics, Inc.<\/b>\n<\/p>\n

\nImmunomic Therapeutics, Inc. (ITI) is a privately held, clinical-stage biotechnology company pioneering the development of vaccines through its proprietary technology platform UNITE, which is designed to utilize the body\u2019s natural biochemistry to develop vaccines that generate broad immune responses. ITI is primarily focused on applying the UNITE platform to oncology indications, where it could potentially have broad applications, including development of antigen-derived antibodies as biologics in a number of cancers. The company has built a pipeline leveraging UNITE with programs in oncology, animal health, infectious disease, and allergy. ITI maintains its headquarters in Rockville, Maryland. For more information, please visit www.immunomix.com<\/a>.\n<\/p>\n

\nAbout Fast Track Designation<\/b>\n<\/p>\n

\nFast Track Designation is designed to facilitate the development and expedite the FDA review of drugs to treat serious conditions and fulfill unmet medical needs, enabling drugs to reach patients earlier. Clinical programs with Fast Track Designation benefit from early and frequent communication with the FDA throughout the regulatory review process. These clinical programs may also be eligible to apply for accelerated approval and breakthrough designation review by the FDA if relevant criteria are met.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nNancy Lillie
\n
Nancy.Lillie@pharmajet.com<\/a>
1-888-900-4321 Option 3\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Vaccine exclusively delivered with the PharmaJet Stratis\u00ae Needle-free Injection System GOLDEN, Colo.–(BUSINESS WIRE)–PharmaJet\u00ae, a company that engineers precision delivery systems that overcome the challenges of vaccine and pharmaceutical companies, today announced that their partner Immunomic Therapeutics received FDA fast track designation (FTD) for the clinical study of their plasmid DNA vaccine ITI-3000 in patients with … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-51928","6":"format-standard","7":"category-industry"},"yoast_head":"\nPharmaJet Partner Immunomic Therapeutics Receives FDA Fast Track Designation for pDNA Vaccine for Skin Cancer - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/pharmajet-partner-immunomic-therapeutics-receives-fda-fast-track-designation-for-pdna-vaccine-for-skin-cancer\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"PharmaJet Partner Immunomic Therapeutics Receives FDA Fast Track Designation for pDNA Vaccine for Skin Cancer - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"Vaccine exclusively delivered with the PharmaJet Stratis\u00ae Needle-free Injection System GOLDEN, Colo.–(BUSINESS WIRE)–PharmaJet\u00ae, a company that engineers precision delivery systems that overcome the challenges of vaccine and pharmaceutical companies, today announced that their partner Immunomic Therapeutics received FDA fast track designation (FTD) for the clinical study of their plasmid DNA vaccine ITI-3000 in patients with ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/pharmajet-partner-immunomic-therapeutics-receives-fda-fast-track-designation-for-pdna-vaccine-for-skin-cancer\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-12-13T16:02:19+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20221213005025\/en\/349464\/21\/50-10057C_PJ_Trademark.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/pharmajet-partner-immunomic-therapeutics-receives-fda-fast-track-designation-for-pdna-vaccine-for-skin-cancer\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/pharmajet-partner-immunomic-therapeutics-receives-fda-fast-track-designation-for-pdna-vaccine-for-skin-cancer\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"PharmaJet Partner Immunomic Therapeutics Receives FDA Fast Track Designation for pDNA Vaccine for Skin Cancer\",\"datePublished\":\"2022-12-13T16:02:19+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/pharmajet-partner-immunomic-therapeutics-receives-fda-fast-track-designation-for-pdna-vaccine-for-skin-cancer\\\/\"},\"wordCount\":612,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/pharmajet-partner-immunomic-therapeutics-receives-fda-fast-track-designation-for-pdna-vaccine-for-skin-cancer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221213005025\\\/en\\\/349464\\\/21\\\/50-10057C_PJ_Trademark.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/pharmajet-partner-immunomic-therapeutics-receives-fda-fast-track-designation-for-pdna-vaccine-for-skin-cancer\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/pharmajet-partner-immunomic-therapeutics-receives-fda-fast-track-designation-for-pdna-vaccine-for-skin-cancer\\\/\",\"name\":\"PharmaJet Partner Immunomic Therapeutics Receives FDA Fast Track Designation for pDNA Vaccine for Skin Cancer - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/pharmajet-partner-immunomic-therapeutics-receives-fda-fast-track-designation-for-pdna-vaccine-for-skin-cancer\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/pharmajet-partner-immunomic-therapeutics-receives-fda-fast-track-designation-for-pdna-vaccine-for-skin-cancer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221213005025\\\/en\\\/349464\\\/21\\\/50-10057C_PJ_Trademark.jpg\",\"datePublished\":\"2022-12-13T16:02:19+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/pharmajet-partner-immunomic-therapeutics-receives-fda-fast-track-designation-for-pdna-vaccine-for-skin-cancer\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/pharmajet-partner-immunomic-therapeutics-receives-fda-fast-track-designation-for-pdna-vaccine-for-skin-cancer\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/pharmajet-partner-immunomic-therapeutics-receives-fda-fast-track-designation-for-pdna-vaccine-for-skin-cancer\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221213005025\\\/en\\\/349464\\\/21\\\/50-10057C_PJ_Trademark.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221213005025\\\/en\\\/349464\\\/21\\\/50-10057C_PJ_Trademark.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/pharmajet-partner-immunomic-therapeutics-receives-fda-fast-track-designation-for-pdna-vaccine-for-skin-cancer\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"PharmaJet Partner Immunomic Therapeutics Receives FDA Fast Track Designation for pDNA Vaccine for Skin Cancer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"PharmaJet Partner Immunomic Therapeutics Receives FDA Fast Track Designation for pDNA Vaccine for Skin Cancer - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/pharmajet-partner-immunomic-therapeutics-receives-fda-fast-track-designation-for-pdna-vaccine-for-skin-cancer\/","og_locale":"en_US","og_type":"article","og_title":"PharmaJet Partner Immunomic Therapeutics Receives FDA Fast Track Designation for pDNA Vaccine for Skin Cancer - Pharma Trend","og_description":"Vaccine exclusively delivered with the PharmaJet Stratis\u00ae Needle-free Injection System GOLDEN, Colo.–(BUSINESS WIRE)–PharmaJet\u00ae, a company that engineers precision delivery systems that overcome the challenges of vaccine and pharmaceutical companies, today announced that their partner Immunomic Therapeutics received FDA fast track designation (FTD) for the clinical study of their plasmid DNA vaccine ITI-3000 in patients with ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/pharmajet-partner-immunomic-therapeutics-receives-fda-fast-track-designation-for-pdna-vaccine-for-skin-cancer\/","og_site_name":"Pharma Trend","article_published_time":"2022-12-13T16:02:19+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20221213005025\/en\/349464\/21\/50-10057C_PJ_Trademark.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/pharmajet-partner-immunomic-therapeutics-receives-fda-fast-track-designation-for-pdna-vaccine-for-skin-cancer\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/pharmajet-partner-immunomic-therapeutics-receives-fda-fast-track-designation-for-pdna-vaccine-for-skin-cancer\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"PharmaJet Partner Immunomic Therapeutics Receives FDA Fast Track Designation for pDNA Vaccine for Skin Cancer","datePublished":"2022-12-13T16:02:19+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/pharmajet-partner-immunomic-therapeutics-receives-fda-fast-track-designation-for-pdna-vaccine-for-skin-cancer\/"},"wordCount":612,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/pharmajet-partner-immunomic-therapeutics-receives-fda-fast-track-designation-for-pdna-vaccine-for-skin-cancer\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221213005025\/en\/349464\/21\/50-10057C_PJ_Trademark.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/pharmajet-partner-immunomic-therapeutics-receives-fda-fast-track-designation-for-pdna-vaccine-for-skin-cancer\/","url":"https:\/\/pharma-trend.com\/en\/pharmajet-partner-immunomic-therapeutics-receives-fda-fast-track-designation-for-pdna-vaccine-for-skin-cancer\/","name":"PharmaJet Partner Immunomic Therapeutics Receives FDA Fast Track Designation for pDNA Vaccine for Skin Cancer - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/pharmajet-partner-immunomic-therapeutics-receives-fda-fast-track-designation-for-pdna-vaccine-for-skin-cancer\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/pharmajet-partner-immunomic-therapeutics-receives-fda-fast-track-designation-for-pdna-vaccine-for-skin-cancer\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221213005025\/en\/349464\/21\/50-10057C_PJ_Trademark.jpg","datePublished":"2022-12-13T16:02:19+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/pharmajet-partner-immunomic-therapeutics-receives-fda-fast-track-designation-for-pdna-vaccine-for-skin-cancer\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/pharmajet-partner-immunomic-therapeutics-receives-fda-fast-track-designation-for-pdna-vaccine-for-skin-cancer\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/pharmajet-partner-immunomic-therapeutics-receives-fda-fast-track-designation-for-pdna-vaccine-for-skin-cancer\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20221213005025\/en\/349464\/21\/50-10057C_PJ_Trademark.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20221213005025\/en\/349464\/21\/50-10057C_PJ_Trademark.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/pharmajet-partner-immunomic-therapeutics-receives-fda-fast-track-designation-for-pdna-vaccine-for-skin-cancer\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"PharmaJet Partner Immunomic Therapeutics Receives FDA Fast Track Designation for pDNA Vaccine for Skin Cancer"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/51928","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=51928"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/51928\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=51928"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=51928"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=51928"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}